SCHEMBL23218814

SCHEMBL23218814

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C)oc2ccc(-c3cccc(CN)n3)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
GAA P10253 3/20 0.39
MAPT P10636 3/20 0.39
GLA P06280 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
DPP4 P27487 2/20 0.36
F2RL3 Q96RI0 2/20 0.36
CFD P00746 1/20 0.35
PTPN1 P18031 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PTGS2 P35354 1/20 0.34
PDE10A Q9Y233 1/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ANO1 Q5XXA6 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852964 1.00 TSHR (0.39) TSHRKDM4EALDH1A1HPGDGAA
SCHEMBL23218071 0.92 F2RL3 (0.37) KDM4EGAAF2RL3PDE10APOLB
SCHEMBL23218130 0.88 TSHR (0.39) TSHRKDM4EALDH1A1HPGDGAA
SCHEMBL23218399 0.87 TSHR (0.41) TSHRKDM4EALDH1A1HPGDGAA
SCHEMBL29852645 0.87 TSHR (0.41) TSHRKDM4EALDH1A1HPGDGAA
SCHEMBL29852791 0.86 CFD (0.43) TSHRKDM4EALDH1A1HPGDGAA
SCHEMBL23218533 0.86 CFD (0.43) TSHRKDM4EALDH1A1HPGDGAA
SCHEMBL23218232 0.84 TSHR (0.40) TSHRKDM4EALDH1A1HPGDGAA
SCHEMBL23218205 0.84 TSHR (0.40) TSHRKDM4EALDH1A1HPGDGAA
SCHEMBL29852953 0.84 TSHR (0.40) TSHRKDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TSHR 1199/4885KDM4E 4172/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TSHR 3148/4885KDM4E 4491/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.